Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 583 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR What to Know About Cancer Care and Research for People 65+:... February 28, 2023 Phytochemicals and Antioxidants December 11, 2020 K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 Load more HOT NEWS Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... Teen Invents ‘Resilience Bra’ To Help Breast Cancer Patients With Post-Mastectomy... 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma
